Protara Therapeutics, Inc.
TARA
$3.22
-$0.05-1.53%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.30% | -8.80% | -7.76% | -8.03% | -10.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.70% | 7.80% | 11.08% | 25.63% | 16.16% |
| Operating Income | -12.70% | -7.80% | -11.08% | -25.63% | -16.16% |
| Income Before Tax | -10.33% | 39.21% | 39.27% | 33.89% | 38.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.33% | 39.21% | 39.27% | 33.89% | 38.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.33% | 39.21% | 39.27% | 33.89% | 38.71% |
| EBIT | -12.70% | -7.80% | -11.08% | -25.63% | -16.16% |
| EBITDA | -12.83% | -7.74% | -11.02% | -25.60% | -16.02% |
| EPS Basic | 32.58% | 53.95% | 46.34% | 34.41% | 39.08% |
| Normalized Basic EPS | 32.58% | 19.54% | 3.99% | -21.37% | -10.23% |
| EPS Diluted | 32.58% | 53.95% | 46.34% | 34.41% | 39.08% |
| Normalized Diluted EPS | 32.58% | 19.54% | 3.99% | -21.37% | -10.23% |
| Average Basic Shares Outstanding | 79.63% | 46.70% | 22.64% | 0.78% | 0.64% |
| Average Diluted Shares Outstanding | 79.63% | 46.70% | 22.64% | 0.78% | 0.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |